🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment

Recruitingn/aAges 18 Years - 75 YearsAllRuijin Hospital
NCT06534489 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Lung cancer is one of the most common malignant tumors worldwide and has the highest mortality rate among malignant tumors. In recent years, with the gradual development of therapeutic modalities such as targeted therapy and immunotherapy, the overall survival of lung cancer patients has improved significantly. However, late tumor staging at the time of diagnosis often leaves patients with only pneumonectomy, which affects the prognosis with a higher rate of postoperative complications than lobectomy, poorer quality of life and the possible loss of the opportunity to continue adjuvant therapy. Our group proposes to conduct this single-arm prospective clinical study to investigate the feasibility, safety and prognosis of the conversion from pneumonectomy to lobectomy after neoadjuvant or induction therapy in patients with operable non-small cell lung cancer.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * The patients voluntarily participate in the study, have good compliance, can cooperate with the requirements of the experiment to complete the observation and follow-up, and sign the informed consent form. * Aged over 18 years old, under 75 years old; male and female are not limited; * Pathologically confirmed non-small cell lung cancer with clinical stage T2-4N0-2, resectable non-small cell lung cancer, potentially needing pneumonectomy and receiving neoadjuvant or induction therapy. * ASA score: Grade I-III; * The cardiopulmonary function evaluation can meet the requirements for radical lung cancer surgery, and the liver and kidney functions are normal. Exclusion Criteria: * Those with serious cardiac, pulmonary, hepatic, and renal dysfunctions, unable to tolerate the surgery; * Those with uncontrollable neurological or psychiatric diseases or mental disorders, poor compliance, and being unable to cooperate and describe the treatment response. * Those who are going to undergo emergency surgery or palliative surgery due to lung abscess or hemoptysis. * Those who have been treated, or are undergoing neoadjuvant or induction radiotherapy or targeted therapy. * Those who have a combined history of other malignant tumors * Those who have a history of thoracic surgery * Those who are pregnant or breastfeeding women * Patients of childbearing age who refuse to use contraception.
💊

What it tests

  • neoadjuvant immuno-chemotherapy and surgery
📍

Where

1 site
Ruijin hospital
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy